Home » Insights » Insights Intercept Blood System
    08/2018- Hospital News

    Clinical efficiency and patient safety of INTERCEPT Blood System

    The INTERCEPT Blood System for platelets has demonstrated clinical efficacy for treating and preventing bleeding in clinical trials and in routine use.1

    While many studies were performed in haematology/oncology patients, this study focused on the clinical efficacy during massive transfusion.

    07/2018- Economics

    The economics of Double Dose Buffy Coat Platelets

    For blood centres seeking a cost-effective way to implement INTERCEPT pathogen inactivation, double dose buffy coat platelet production may offer a solution.

    What is a double dose buffy coat platelet unit?

    A platelet concentrate with sufficient platelet count to result in 2 therapeutic doses after pathogen inactivation with the INTERCEPT Blood System.

    The double dose buffy coat platelet...

    07/2018- Hospital News

    INTERCEPT Blood System  for massively transfused patients

    Large Austrian Medical Centre publishes study results on component utilization and patient safety after adoption of platelet pathogen inactivation.

    The Medical University Hospital in Innsbruck has evaluated the influence of the INTERCEPT™ Blood System for platelets on component utilization and patient safety. The effectiveness of conventional vs. INTERCEPT™-treated platelets was analyzed...

    07/2018- Cerus

    2 million Swiss francs to  develop a whole blood PI system in Africa

    The Swiss Red Cross Humanitarian Foundation has awarded a grant of 2 million Swiss Francs to Cerus, the University Hospital of Basel, and the Swiss Transfusion SRC to complete the necessary clinical studies to develop a whole blood pathogen inactivation system for use in Africa. 

    07/2018- Cerus

    $180 million to support  development of Cerus' RBC programme

    Cerus has entered an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support Cerus’ clinical development program for pathogen reduction of red blood cell (RBC) components, including access to funding that could support various activities, such as the funding of studies necessary to support an FDA submission and to accelerate commercial scale.

    07/2018- Cerus

    Cerus for charity

    At Cerus, we work to enhance and save lives. We usually do this by advancing the safety, efficacy and availability of blood, but this time I’d like to ask for your support to save and enhance life in a different way.